View Older Stories View More Recent Stories
-
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
-
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA Resubmission of LYMPHIR for Treatment of Adults with R/R Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Granted Nasdaq Hearing
-
Citius Pharmaceuticals (CTXR) Wins $2.4M via NJ Economic Development Program
-
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
-
Citius Pharmaceuticals (CTXR) Files S-3 Shelf to Replace Prior Shelf Registration
-
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
-
Citius Pharmaceuticals (CTXR) Files $250M Mixed Shelf
-
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
-
Citius Pharmaceuticals, Inc. (CTXR) Reports Q1 Loss of $0.06
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Resubmits the BLA for LYMPHIR
-
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Appoints Robert J. Smith to its Board
-
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
-
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
-
Citius Pharmaceuticals (CTXR) Announces Publication of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor
-
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
-
Citius Pharmaceuticals (CTXR) to Merge Wholly Owned Subsidiary with TenX Keane Acquisition (TENK) to Form Publicly Listed Citius Oncology, Inc.
-
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
-
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
-
Citius Pharmaceuticals (CTXR) Announces Passing of Board Member Howard Safir
-
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
-
Citius Pharmaceuticals (CTXR) Receives Regulatory Guidance from the FDA for the Planned Resubmission of the BLA for LYMPHIR
-
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
-
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
-
Citius Pharmaceuticals, Inc. (CTXR) Reports In-Line Q3 EPS
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial
-
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
-
Citius Pharmaceuticals (CTXR) Receives CRL for LYMPHIR
-
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Re
-
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes
-
Citius Pharmaceuticals (CTXR) Reports Positive Results from the Phase 2b Study of Halo-Lido
-
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids
-
Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Announces 12.5M Share Offering at $1.20/sh
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date
-
Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date
-
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals (CTXR) Advances Efforts to Spin Off I/ONTAK into Standalone Company
-
Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company
-
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
